Lapatinib Newbury approved by the Swedish Health Authorities

MFN Publicerad: 24 Mar 2023 11:45

Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Lapatinib Newbury 250 mg film-coated tablets in Sweden as the first country in a Scandinavian registration procedure. Approvals in Norway and Denmark are expected to follow upon finalized national reviews.

Lapatinib is a targeted cancer drug, also known by its brand name Tyverb, that is used to treat certain types of breast cancer, where tumors overexpress HER2.

“Lapatinib is a terrific addition to the existing high-value oncology product portfolio, and we are proud to further strengthen our commitment within oncology. Based on this positive progress, we will proceed to launch this product, within respective markets as soon as regulatory exclusivities and patents allow us.” says Mr Lars Minor CEO of Newbury.

Newbury currently has licensed ten (10) products within oncology and plan to offer treatment options for both solid and hematological malignancies (e.g. breast cancer, myeloma, leukemia, prostate cancer and thyroid cancer).

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at [email protected] or +46 (0) 40 200 250.

Börskollen

För dig med koll på börsen

Pressmeddelande

Lapatinib Newbury approved by the Swedish Health Authorities

Bifogade filer

Nyheter om Newbury Pharmaceuticals

Läses av andra just nu

Om aktien Newbury Pharmaceuticals

Senaste nytt